15 Reasons Dr. Cazzell Should Touch YOUR Feet Every Month
- Dr. Cazzell is a Podiatrist and Fellowship Trained Diabetic Foot Salvage Surgeon.
- He is a Global Key Opinion Leader on the Diabetic Lower Limb, Advanced Wound Healing and Tissue Repair.
- Founder of LPP Clinical Research. National and Principal Investigator on over 60+ clinical research trials and Post Market Surveillance Studies Dedicated to Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), and Soft Tissue Infections of the Foot.
- Numerous Publications. International Speaker. Medical Advisory Boards. Study and Protocol Design.
- Recently Completed a Multiyear Diabetic Foot Research Sabbatical Studying Current Best Practice Wound and Amputation Prevention Strategies on the At-Risk Diabetic and Advanced Age Foot. Currently, Zero Consensus Regarding Best Practice Preventive Strategies.
- Most “Healthy Diabetic and Advanced Age Feet” Do Not Qualify for Foot Care Services by Insurance Companies (Including Medicare/Medi-Cal). This is When We Need them.
- The At-Risk Foot is Covered by Most Insurance Companies for Bi-Annual Routine Diabetic Foot Examinations (Again, Zero Consensus Regarding Best Practice Preventive Strategies). This is Too Late!
- Research Suggests a Structured Foot Care Program Could Reduce Rates of Amputation by 75%.
- Creation of a Structured Comprehensive Medical Foot Care Program Combined with Resort Spa Pedicure on a Monthly Basis WILL Have a Dramatic Impact on Valley Residents.
- Private Label Skincare Line to Meet the Needs of the Dry, Dehydrated, Diabetic and Advanced Age At-Risk Foot.
- No Referrals. No Insurance. Membership Based. Limited Availability. Monthly Visits. Expected Opening June/July 2021.
- Our Mission: Increase Wound and Amputation Free Days, by Performing Convenient, Routine, Affordable, Comprehensive Medical Foot Care on the At-Risk Foot (Medical Pedicures + Therapeutic Skincare).
- SMC // EXTREMITY is Unique. Nail Salons Do Not Possess the Education, Training, Diagnostic, or Procedural Skillset to Maximize Your Foot Wellness.
- Again, SMC // EXTREMITY is Unique. Podiatry Practices are Unable to Provide the Depth and Frequency of Care Needed.
- Lastly, If I Can Give an Exhaustive Comprehensive Lower Extremity Examination While Delivering the Best Spa Pedicure You’ve Never Had, I Will See You Early (prior to wounding) and Often (monthly).
Watch the following educational video series (coming soon) regarding foot complications as a result of Diabetes and Advanced Age, and it starts to all make sense.
- Peripheral Neuropathy
- Peripheral Arterial Disease (PAD)
- Foot Deformity
- Trophic Changes (Skin, Nail, and Hair impairment)
- History of Diabetic Foot Ulceration (DFU)
- History of Lower Extremity Amputation
- Chronic Kidney Disease (CKD) / Dialysis
- Diabetic Retinopathy (DR) / Macular Degeneration
If our Foot Smart video series and 15 reasons to see us isn’t enough to convince you of our knowledge and your need, just look below. We’ve been really busy contributing to the at-risk foot all over the world!
Published Research Articles
Feasibility and Efficacy of a Smart Mat Technology to Predict Development of Diabetic Plantar Ulcers
http://care.diabetesjournals.org/content/40/7/973
Baseline factors affecting closure of venous leg ulcers
https://www.sciencedirect.com/science/article/pii/S2213333X17303517
Phase 3 evaluation of HP802-247 in the treatment of chronic venous leg ulcers
http://onlinelibrary.wiley.com/doi/10.1111/wrr.12467/abstract
Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis
http://www.magonlinelibrary.com/doi/abs/10.12968/jowc.2016.25.Sup7.S18
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750365/
The Management of Diabetic Foot Ulcers with Porcine Small Intestine Submucosa Tri-Layer Matrix: A Randomized Controlled Trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651054/
Central talar dome lesions: a unique surgical approach with incorporation of a talar allograft for joint reconstitution and restoration of function
https://www.ncbi.nlm.nih.gov/pubmed/21406705
A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers
http://onlinelibrary.wiley.com/doi/10.1111/iwj.12843/full
A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator
http://onlinelibrary.wiley.com/doi/10.1111/wrr.12551/full
Clinical Research Trials
Principal Investigator for the following trials:
A phase 3 randomized, placebo-controlled, blinded study to investigate the safety and efficacy of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with an infected foot ulcer
A phase IIb, prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
A multicenter prospective, randomized, controlled, comparative parallel study of dehydrated human amnion/chorion membrane (dHACM) wound graft in the management of diabetic foot ulcers
A phase-3 prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of Curexcell® as an adjunct to good ulcer care measures in treating chronic venous leg ulcers
A multicenter, randomized, controlled, open-label trial to assess the clinical effectiveness of DermACELL®, conventional care wound management, and Graftjacket® in subjects with chronic wounds in the lower extremities
An evaluation of tissue engineering approaches for treatment of neuropathic diabetic foot ulcers resistant to standard of care: a prospective, randomized controlled trial
A phase III, multinational, multicenter, randomized, double-blind, parallel-group, sham-controlled study to evaluate the safety, tolerability and efficacy of Curexcell® as an adjunct to good wound care measures in treating lower extremity chronic ulcers in adults with diabetes mellitus
A phase 3 randomized, double blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers >12 cm2 to ≤ 36 cm2
A phase 3 randomized, double blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers
A non-interventional safety study providing 12 months follow-up from first exposure to HP802-247 in subjects with venous leg ulcer
A multi-center, randomized, controlled clinical trial to evaluate the safety and effectiveness of Integra® dermal regeneration template for the treatment of neuropathic diabetic foot ulcers
In-Balance VLU inflammation, bacteria, & angiogenesis effects in launching venous leg ulcer healing
Restoring equilibrium and wound stimulation to promote healing of non-healing DFUs
A phase II, randomized, controlled, multi-center study of the safety and efficacy of topically applied Mebo® wound ointment compared to standard of care in subjects with diabetic foot ulcers
Clinical outcomes associated with enzymatic debridement of diabetic foot ulcers for up to 12 weeks with clostridial collagenase (Santyl®) ointment
A phase 2 multicenter, randomized, double-blind, placebo–controlled, dose range finding study to evaluate the efficacy and safety of intramuscular injection of human placenta-derived cells (PDA-002) in subjects who have diabetic foot ulcer with peripheral arterial disease
Epifix® vs. standard of care in the treatment of venous leg ulcers
Phase 3 study evaluating efficacy and safety of DSC127 compared with vehicle and with standard-of-care in diabetic foot ulcers (Stride 2)
Open-label study in diabetic foot ulcers (DFU), to evaluate safety of 0.03% DSC127 topical gel in chronic use (Stride 5)
In-home assessment of a smart foot mat for prevention of diabetic foot ulcers
A prospective, randomized, double-blind multicenter study comparing continuous diffusion of oxygen (CDO) therapy to standard moist wound therapy (MWT) in the treatment of diabetic foot ulcers
The NuTech NuShield and Affinity membrane product evaluation for the treatment of neuropathic diabetic foot ulcers (DFUs)
A randomized, double-blind, multicenter, superiority, placebo-controlled phase 3 study of pexiganan cream 0.8% applied twice daily for 14 days in the treatment of adults with mild infections of diabetic foot ulcers
A randomized, prospective, multi-center feasibility study of APT001 plasma/nitric oxide therapy for the treatment of diabetic foot ulcers
A phase 1b/2a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of adjunctive treatment with topically applied MBN-101 in subjects with moderate to severe diabetic foot infection (DFI)
A randomized trial comparing a dual action pneumatic compression system against multi-layer bandaging system: A non-inferiority study
A prospective trial measuring the clinical outcomes for DermACELL AWM in chronic Wagner Grade 3/4 diabetic foot ulcers
A postmarket, prospective evaluation of human placental membrane tissue used as a wound cover for chronic foot ulcers in patients with diabetes
A multicenter prospective, randomized, controlled, comparative parallel study of dehydrated human umbilical cord allograft in the management of diabetic foot ulcers
An evaluation of Biovance, a dehydrated decellularized human amniotic membrane allograft, in diabetic foot ulcers
A pivotal study of the use of plasma/nitric oxide therapy as produced by the APT001 plasma/nitric oxide generator in adult subjects with a diabetic foot ulcer
A prospective, multi-center, randomized controlled trial evaluating the use of Primatrix dermal repair scaffold for the management of diabetic foot ulcers
A phase 2a, randomized, double-blind, multicenter, placebo and active controlled study to assess analgesic efficacy and safety of ASP3662 in subjects with painful diabetic peripheral neuropathy
A randomized, open label controlled trial of Oasis® ultra tri-layer matrix compared to standard care in the healing of diabetic foot ulcers
A phase III, prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
A phase III, prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of Achilles tendonitis
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer: A 10-week randomized, double-blind, placebo-controlled, prospective, international, multicentre, phase IIa study
A prospective, multi-center, double-blind, randomized, placebo-controlled trial comparing two doses of VF001-DP to placebo as an adjunct to standard care in patients with chronic venous leg ulcers
Presentations
Treatment Methods and Experience Using a Novel Aggregating Powder Dressing, as a Primary Dressing, Over a Single Layer Skin Equivalent. Abstract presented at American College of Foot and Ankle Orthopedics and Medicine Scientific Conference, Orlando, FL, July 2009.
A Randomized, Open Label, Controlled Trial of a Tri‐Layer Extracellular Matrix vs. Standard Care in the Healing of Diabetic Foot Ulcers. Abstract presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.
A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix Versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers: An Interim Analysis. Abstract presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.
A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers. Abstract presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.
An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers (DFUs) Resistant to Standard of Care (SOC): An Interim Analysis of a Prospective, Randomized Controlled Trial. Abstract presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at John A. Boswick Burn Symposium, Maui, HI, February 2016.
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at Diabetic Limb Salvage Symposium, Georgetown University, Washington, DC, April 2016.
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results Presented at The Symposium on Advanced Wound Care, Atlanta, GA, April 2016.
Prospective Study Exploring Use of a Sterile, Room Temperature, Acellular Dermal Matrix* to Treat Chronic Wagner Grade 3 & 4 Diabetic Foot Ulcers. Abstract accepted for presentation at The Symposium on Advanced Wound Care, Charlotte, NC, April 2018.